免疫疗法在妊娠滋养细胞肿瘤中的进展。
Progress of immunotherapies in gestational trophoblastic neoplasms.
机构信息
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, People's Republic of China.
Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China.
出版信息
J Cancer Res Clin Oncol. 2023 Nov;149(16):15275-15285. doi: 10.1007/s00432-023-05010-8. Epub 2023 Aug 18.
BACKGROUND
Different from other malignant gynecologic tumors, gestational trophoblastic neoplasms (GTNs) exhibit an exceptionally high cure rate primarily through chemotherapeutic interventions. However, there exists a small subset of refractory GTNs that do not respond to conventional chemotherapies. In such cases, the emergence of immunotherapies has demonstrated significant benefits in managing various challenging GTNs.
PURPOSE
This article aims to provide a comprehensive and systematic review of the immune microenvironment and immunotherapeutic approaches for GTNs. The purpose is to identify potential biomarkers that could enhance disease management and summarize the available immunotherapies for ease of reference.
METHODS
We reviewed the relevant literatures toward immunotherapies of GTNs from PubMed.
CONCLUSION
Current immunotherapeutic strategies for GTNs mainly revolve around immune checkpoint inhibitors (ICIs) targeting programmed death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1). Prominent examples include avelumab, pembrolizumab, and camrelizumab. However, existing researches into the underlying mechanisms are still limited.
背景
与其他妇科恶性肿瘤不同，妊娠滋养细胞肿瘤（GTN）主要通过化疗干预，具有极高的治愈率。然而，一小部分难治性 GTN 对常规化疗无反应。在这种情况下，免疫疗法的出现已证明在治疗各种具有挑战性的 GTN 方面具有显著益处。
目的
本文旨在全面系统地综述 GTN 的免疫微环境和免疫治疗方法。目的是确定可能增强疾病管理的潜在生物标志物，并总结现有的免疫疗法，以便参考。
方法
我们查阅了 PubMed 上关于 GTN 免疫治疗的相关文献。
结论
目前 GTN 的免疫治疗策略主要围绕程序性死亡受体 1（PD-1）和程序性细胞死亡配体 1（PD-L1）的免疫检查点抑制剂（ICI）。突出的例子包括avelumab、pembrolizumab 和 camrelizumab。然而，对潜在机制的现有研究仍然有限。
Zotero 插件